肝繊維症(Liver Fibrosis)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Liver Fibrosis – Overview 8
Pipeline Products for Liver Fibrosis – Comparative Analysis 9
Liver Fibrosis – Therapeutics under Development by Companies 10
Liver Fibrosis – Therapeutics under Investigation by Universities/Institutes 12
Liver Fibrosis – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Liver Fibrosis – Products under Development by Companies 15
Liver Fibrosis – Products under Investigation by Universities/Institutes 18
Liver Fibrosis – Companies Involved in Therapeutics Development 19
Advinus Therapeutics Ltd. 19
Angion Biomedica Corp. 20
BerGenBio AS 21
BiOrion Technologies B.V. 22
Celgene Corporation 23
Digna Biotech, S.L. 24
FibroGen, Inc. 25
Galectin Therapeutics, Inc. 26
Genfit SA 27
GenKyoTex S.A. 28
Gilead Sciences, Inc. 29
GNI Group Ltd. 30
La Jolla Pharmaceutical Company 31
LG Life Sciences, Ltd. 32
Nitto Denko Corporation 33
Pharmaxis Limited 34
Promedior, Inc. 35
Promethera Biosciences S.A. 36
ProMetic Life Sciences Inc. 37
RXi Pharmaceuticals Corporation 38
TCM Biotech International Corp 39
Vascular Biogenics Ltd. 40
Virobay Inc. 41
Liver Fibrosis – Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ANG-3281 – Drug Profile 52
ANG-3298 – Drug Profile 53
ANG-4011 – Drug Profile 54
BGB-324 – Drug Profile 55
BOT-162 – Drug Profile 56
BOT-191 – Drug Profile 57
CC-539 – Drug Profile 58
CC-90001 – Drug Profile 59
CIGB-500 – Drug Profile 60
CT-140 – Drug Profile 61
DB-036 – Drug Profile 62
DCBBO-1202 – Drug Profile 63
disitertide – Drug Profile 64
Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis – Drug Profile 66
F-351 – Drug Profile 67
FG-3019 – Drug Profile 69
GCS-100 – Drug Profile 71
GFT-505 – Drug Profile 73
GKT-137831 – Drug Profile 76
GKT-901 – Drug Profile 77
GM-CT-01 – Drug Profile 78
GM-CT-02 – Drug Profile 81
GR-MD-01 – Drug Profile 82
GR-MD-02 – Drug Profile 83
HepaStem – Drug Profile 85
KW-0 – Drug Profile 87
LC-280126 – Drug Profile 88
LJPC-201 – Drug Profile 90
melittin – Drug Profile 91
ND-L02s0201 – Drug Profile 92
NPLC-0393 – Drug Profile 94
P-17 – Drug Profile 95
PBI-4050 – Drug Profile 97
PRI-724 – Drug Profile 98
PRM-151 – Drug Profile 100
PXS-4728A – Drug Profile 102
PXS-5033A – Drug Profile 103
RXI-209 – Drug Profile 104
simtuzumab – Drug Profile 105
Small Molecule for Liver Fibrosis – Drug Profile 107
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis – Drug Profile 108
Stem Cell Therapy for Liver Fibrosis and Liver Diseases – Drug Profile 109
Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology – Drug Profile 110
TCM-808FB – Drug Profile 111
TGFTX-4 Program – Drug Profile 112
VB-201 – Drug Profile 113
VBY-376 – Drug Profile 115
VBY-825 – Drug Profile 116
Liver Fibrosis – Recent Pipeline Updates 117
Liver Fibrosis – Dormant Projects 150
Liver Fibrosis – Discontinued Products 151
Liver Fibrosis – Product Development Milestones 152
Featured News & Press Releases 152
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160